The ultra-rapidly activating delayed rectifier K + current I Kur (encoded by K v 1.5 or KCNA5) plays an important role in human atrial repolarization. The present study investigates the regulation of this current by protein tyrosine kinases (PTKs).
Introduction
The ultra-rapidly activating delayed rectifier current I Kur was initially reported in human atrial myocytes and later found in atria, but not in the ventricles of the human heart (Li et al., 1996b) . This current contributes to the repolarization of human atrial action potentials (Feng et al., 1997; Wettwer et al., 2004; Li et al., 2008) . I Kur is carried by K v 1.5 (KCNA5) channels (Fedida et al., 1993; Snyders et al., 1993; Feng et al., 1997) . Loss-of-function and/or gainof-function K v 1.5 mutations may increase atrial fibrillation susceptibility (Olson et al., 2006; Christophersen et al., 2013) and so K v 1.5 channels are attractive targets for the treatment of atrial arrhythmias Schumacher et al., 2009; Tamargo et al., 2009; Loose et al., 2014) . Our earlier study demonstrated that stimulation of β-adrenoceptors increases, whereas α-adrenoceptor stimulation decreases, human atrial I Kur via activating protein kinase A and protein kinase C respectively (Li et al., 1996a) . The up-regulation by protein kinase A and the down-regulation by protein kinase C have been confirmed in K v 1.5 channels expressed in Xenopus laevis oocytes with K v β1.3 (Kwak et al., 1999) or K v β1.2 subunits (Williams et al., 2002) . A recent study showed that AMP-activated protein kinase down-regulated K v 1.5 channels via activating the ubiqutin ligase Nedd4-2 with subsequent clearance of channel protein from the cell membrane (Mia et al., 2012) .
Receptor protein tyrosine kinases (PTKs) such as the EGF receptor (EGFR) kinase, and non-receptor PTKs (e.g. the Src family kinases) (Hubbard and Till, 2000) play crucial roles in mediating cell growth, embryonic development, differentiation, metabolism, immune system function and oncogenesis. In addition, PTKs regulate transmembrane ion channels (Davis et al., 2001; Levitan, 1994) . EGFR PTKs regulate several ion channels, including those carrying the cardiac voltage-gated sodium current (I Na ) (Liu et al., 2007) , K ir 2.3 and K ir 2.1 (Zhang et al., 2011a,b) , recombinant human cardiac I Ks (hKCNQ1/hKCNE1) (Dong et al., 2010) and the human EAG1 (K v 10.1) channels . Src family kinases also participate in regulation of hERG channels and cardiac transient outward potassium current (I to , carried by hK v 4.3 channels) ). An earlier report demonstrated that Src TK was associated with native hK v 1.5 channels in human myocardium and cloned hK v 1.5 channels. Tyrosine phosphorylation of hK v 1.5 channels suppressed the channel current in cells coexpressing v-Src (Holmes et al., 1996) .
The present study investigated effects of EGFR TK and Src family kinases on I Kur /hK v 1.5 channels using pharmacological tools. Our results demonstrated that genistein (a broad spectrum PTK inhibitor) and AG556 (a highly selective EGFR kinase inhibitor) inhibited I Kur /hK v 1.5 current, whereas the inhibitor of Src family kinases, PP2, increased the current, by decreasing phosphorylation of hK v 1.5 channels.
Methods

Human atrial myocyte isolation
The protocols for obtaining human atrial tissues was approved by the Ethics Committee of the University of Hong Kong (UW-10-174) with patients' consent. The investigation follows the principles outlined in the Declaration of Helsinki (see Cardiovascular Research 1997;35:2-4) for using human tissue. Human right atrial tissues were collected from patients undergoing coronary artery bypass grafting. Human atrial myocytes were enzymatically dissociated using the procedure as previously described (Li et al., 1996a . The isolated myocytes were kept at room temperature in a high-potassium medium for at least 2 h before the electrophysiological recordings and randomly used for testing the effects of genistein, AG556, PP2 and/or orthovanadate on human atrial I Kur .
Cell culture, mutagenesis and gene transfection
The HEK 293 cell line (Tang et al., 2007; Wu et al., 2011) stably expressing hKv1.5/pBK CMV vector provided by Dr M. Tamkun (Colorado State University, CO, USA) was cultured with DMEM (Invitrogen, Hong Kong) containing 400 μg·mL À1 G418 (Sigma-Aldrich, St Louis, MO, USA) and 10% fetal bovine serum. Cells for electrophysiological recording were seeded on a glass cover slip.
The high-potential tyrosine phosphorylation sites of hK v 1.5 channels were predicted with NetPhos 2.0 software (www.cbs.dtu.dk/cgi-bin). Mutants of hK v 1.5 channels were generated using the site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA), and each mutant was confirmed via full Tables of Links   TARGETS Voltage-gated ion channels DNA sequencing analysis (Gene Centre, University of Hong Kong) as described previously (Zhang et al., 2011b; Wu et al., 2013) . The mutants Y155F, Y521F, Y601F or Y155F-Y521F-Y601F were transiently transfected (10 μL of Lipofectamine 2000 with 4 μg of the plasmid) into HEK 293 cells for electrophysiological recording.
Electrophysiology
I Kur and hK v 1.5 current were recorded using the experimental conditions and procedures as described previously (Li et al., 1996a; Wu et al., 2011) . Briefly, atrial myocytes or HEK 293 cells were transferred into the cell chamber and superfused with Tyrode's solution. Whole-cell configuration was established by a gentle suction after obtaining a gigaohm seal. Series resistance (3-5 MΩ) was compensated by 50-80% to reduce voltage errors. The data of membrane electrical signals were acquired using an EPC-10 amplifier and Pulse software (Heka Elektronik, Lambrecht, Germany). All the experiments were conducted at room temperature (22-24°C). The data obtained in cells with unstable R s and/or leakage current increased during experiments were discarded for analysis.
Immunoprecipitation and Western blots
The immunoprecipitation and Western blots were performed following the procedure described previously (Liu et al., 2007; Wu et al., 2012) . Briefly, samples of HEK 293 cells stably expressing hK v 1.5 channels and grown to 70-80% confluence, were treated with the different compounds (30 min at room temperature) and then detached and centrifuged (4°C). After the cell pellet was lysed (Liu et al., 2007; Wu et al., 2012) , the protein lysate was quantified with a protein assay reader (Bio-Rad Laboratories, Hercules, CA, USA) and diluted to equal concentrations. Proteins were immunoprecipitated with 2 μg anti-hK v 1.5 channel antibody (NeuroMab, Davis, CA, USA) and protein A/G beads (100 μL, Upstate) overnight at 4°C. Immunoprecipitated proteins bound to pelleted protein A/G beads were washed with PBS, denatured in Laemmli sample buffer, separated with SDS-PAGE and electroblotted onto nitrocellulose membranes. The immunoblots were probed with anti-phosphotyrosine antibody (1:2000; Cell Signaling Technology Inc., Danvers, MA, USA) overnight at 4°C in the blocking medium containing 5% BSA in Tris buffered saline (TBS) and Tween 20 and subsequently treated with goat antimouse IgG-HRP antibody (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature. Blots were developed with enhanced chemiluminescence (GE Healthcare, Hong Kong) and exposed on X-ray film (Fuji Photo Film GmbH). The blots were then stripped and reprobed with the anti-hK v 1.5 antibody to determine total hK v 1.5 channel proteins. The film was scanned, imaged by a Bio-Imaging System (Syngene, Cambridge, UK) and analysed via Gene Tools software (Syngene).
Data and statistical analysis
The data collection and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data are presented as mean ± SEM. A group size of number of 5 or more was determined based on previous experience Zhang et al., 2012) with SigmaPlot 12.5 (SPSS Science, Chicago, IL, USA). Paired and/or unpaired Student's two-tailed t-test was used as appropriate to determine the statistical significance of differences between two group means. One-way ANOVA for multiple groups was followed by Tukey's test. A value of P < 0.05 was considered to indicate statistical significance.
pyrimidin-4-amine (PP2) was obtained from Tocris Bioscience (Bristol, UK). All other compounds were obtained from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions of genistein (100 mM), daidzein (100 mM), AG556 (100 mM) and PP2 (10 mM) were prepared in DMSO and then aliquoted and stored at À20°C. Aqueous stock solutions of sodium orthovanadate (100 mM) was prepared and pH was adjusted to 9.0 with HCl.
Tyrode's solution contained the following: (mM) NaCl 140, KCl 5.4, MgCl 2 1.0, CaCl 2 1.8, HEPES 5.0 and glucose 10 (pH adjusted to 7.3 with NaOH). The pipette solution contained the following: (mM) KCl 20, K-aspartate 110, MgCl 2 1.0, HEPES 10, EGTA 5, GTP 0.1, Na 2 -phosphocreatine 5 and Mg-ATP 5 (pH adjusted to 7.2 with KOH).
Results
Effect of genistein on I Kur
The effect of genistein (a broad spectrum PTK inhibitor) on I Kur was investigated in human atrial myocytes. The time course of I Kur at +50 mV ( Figure 1A ) was determined in a representative human atrial myocyte with the voltage protocol (inset) in the absence and presence of 30 μM genistein. The current was gradually decreased by genistein, and the inhibition reached a steady-state level in 5 min and almost fully recovered on washout. Figure 1B displays the family of voltagedependent I Kur recorded in a representative cell with the voltage steps as shown in the inset in the absence (control) and presence of 10, 30 and 100 μM genistein. The current was inhibited by genistein in a concentration-dependent manner.
The percentage values of current inhibition, measured (+50 mV, n = 6) at the steady-state current of I Kur at end of voltage step in cells treated with 3, 10, 30 and 100 μM genistein, are illustrated in Figure 1C . Significant inhibition was observed at 10-100 μM (n = 6, P < 0.05 vs. control).
To determine whether the I Kur reduction by genistein, as previously observed in rat cardiac K v currents , is related to PTK inhibition, we tested daidzein (a PTK-inactive analogue of genistein) in human atrial myocytes. Daidzein at 30 μM had no inhibitory effect on I Kur, whereas genistein at 30 μM markedly suppressed this current in the same myocyte (Figure 2A ), suggesting that PTK inhibition is likely to be involved in the decreased I Kur induced by genistein.
Orthovanadate (a protein tyrosine phosphatase inhibitor) was then used to determine whether I Kur inhibition induced by genistein could be reversed by this compound. Orthovanadate at 1 mM significantly reversed the I Kur reduction induced by 30 μM genistein ( Figure 2B ). Figure 2C illustrates the percentage values of current amplitude (+50 mV) with daidzein, genistein and genistein plus orthovanadate or orthovanadate alone. No significant inhibition of I Kur was observed with 30 μM daidzein (n = 5, P > 0.05). Orthovanadate (1 mM) alone did not affect I Kur significantly (n = 6, P > 0.05 vs. control), while it reversed I Kur inhibition by 30 μM genistein (n = 7, P < 0.05 vs. genistein alone). These results suggest that the I Kur reduction by 30 μM genistein is a result of both PTK-dependent and -independent inhibition.
Effect of AG556 on human atrial I Kur
The human atrial I to is inhibited by the highly selective EGFR kinase inhibitor AG556. Here we determined the effects of AG566 on I Kur in human atrial myocytes. Figure 3A shows the time course of I Kur recorded in a representative cell with the voltage protocol shown in the inset before and after application of 10 μM AG556. The current was gradually decreased by AG556, and the inhibition was fully reversed on washout. Figure 3B displays the family of voltage-dependent I Kur recorded in a typical experiment with the voltage protocol shown in the inset in the absence (control) and presence of 3, 10 and 30 μM AG556. AG556 decreased human atrial I Kur in a concentration-dependent manner. Figure 3C illustrates the current inhibition (+50 mV) in cells treated with 1, 3, 10 and 30 μM AG556.
Figure 1
Inhibition of human atrial I Kur by genistein. (A) Time course of I Kur recorded in a typical experiment with a 100 ms prepulse to +40 mV from À50 mV to inactivate I to , followed by 200 ms test pulse to +50 mV (inset) after a 10 ms interval every 15 s. The cell was treated with 30 μM genistein. I Kur traces at corresponding time points are shown in right side of the panel. (B) Family of I Kur (capacitance compensated) at various depolarization voltages (a 100 ms prepulse to +40 mV to inactivate I to , followed by 200 ms test pulses to between À40 and +50 from À50 mV after a 10 ms interval and then to À40 mV in a typical experiment) in the absence and presence of 10, 30 and 100 μM genistein. (C) Percent values of I Kur at +50 mV in cells treated with 3, 10, 30 and 100 μM genistein (n = 6). *P < 0.05, significantly different from control.
Significant current reduction was observed with 3-30 μM AG556 (n = 6, P < 0.05 vs. control). Figure 3D shows the time course of I Kur recorded in another typical experiment before and after application of 10 μM AG556, and AG556 plus 1 mM orthovanadate. AG556 gradually reduced I Kur , and the current reduction was significantly reversed by 1 mM orthovanadate. Figure 3E illustrates the I Kur at +50 mV (as % control) before and after application of 10 μM AG556 and AG556 plus 1 mM orthovanadate. AG556 decreased the current (n = 6, P < 0.05 vs. control), and this inhibition was reversed by orthovanadate (n = 6, P < 0.05 vs. AG556 alone). These results reveal that the decrease in I Kur caused by 10 μM AG556 is mostly a result of EGFR kinase inhibition with a much smaller PTK-independent inhibition.
Inhibition of hK v 1.5 current by genistein and AG556
The human cardiac I Kur is carried by K v 1.5 channels, encoded by the KCNA5 gene (Fedida et al., 1993; Feng et al., 1997) . Thus, we determined whether hK v 1.5 channel current is affected by genistein or AG556 and whether their effects can be reversed by orthovanadate in HEK 293 cells stably expressing hK v 1.5 channels. Figure 4A shows that the family of voltage-dependent hK v 1.5 current was reversibly inhibited by 30 μM genistein and the inhibition was reversed by 1 mM orthovanadate ( Figure 4B ).
Voltage-dependent hK v 1.5 current was also reversibly inhibited by 10 μM AG556 ( Figure 4C ). Figure 4D displays the time course of hK v 1.5 current in a representative cell. AG556 at 10 μM gradually inhibited hK v 1.5 current, and the inhibition was reversed by orthovanadate (1 mM). The result was similar to I Kur in human atrial myocytes ( Figure 3D ). Figure 4E shows the hK v 1.5 current (+50 mV), as %con-trol, in cells treated with 30 μM genistein, genistein plus 1 mM orthovanadate, orthovanadate alone, 10 μM AG556 or AG556 plus orthovanadate. Orthovanadate, as in human atrial I Kur , had no effect on hK v 1.5 channel current. Genistein inhibited hK v 1.5 current at +50 mV (n = 9, P < 0.05 vs. control), and this inhibition was reversed by orthovanadate (n = 9, P < 0.05 vs. genistein alone). The orthovanadateinsensitive fraction of genistein-induced current reduction indicates a PTK-independent inhibition of hK v 1.5 channels by 30 μM genistein, as observed in human atrial I Kur .
AG556 at 10 μM decreased the current (n = 8, P < 0.05 vs. control), and the inhibitory effect was reversed by 1 mM orthovanadate (n = 8, P < 0.05 vs. AG556 alone), showing a small PTK-independent reduction. These results indicate that hK v 1.5 channels expressed in HEK 293 cells, similar to I Kur , are inhibited by genistein or AG556 via PTK-dependent and PTK-independent mechanisms. The PTK-independent effect of genistein on I Kur and hK v 1.5 channels is also reflected by a delayed time of the current to peak (closed channel blocking, Figures 1A and B and 4A and B) , while the direct inhibition of hK v 1.5 channels by AG556 is reflected by an increased current inactivation (open channel blocking, Figure 4C and D).
Effects of PP2 on I Kur and hK v 1.5 channels Whether PP2 (a Src family kinase inhibitor) could also affect I Kur /hK v 1.5 current was determined in human atrial myocytes and HEK 293 cells expressing hK v 1.5channels. Figure 5A shows the family of voltage-dependent I Kur recorded in a typical experiment in the absence and presence of 1 μM PP2 [a concentration 200 times higher (Hanke et al., 1996) than the EC 50 for inhibiting Src-related kinases]. A high concentration of PP2 is usually required for Src family kinase inhibition in experiments at cellular level (Du et al., 2004; Zhang et al., 2008; Zhang et al., 2012) , perhaps because PP2 does not easily cross the cell membrane. It is interesting to note that I Kur was slightly increased by PP2 (7 min superfusion), and the enhancement was also reversed by coapplication of 1 mM orthovanadate. Similar results were Figure 5B ). Figure 5C shows the time course of hK v 1.5 current recorded in an HEK 293 cell expressing hK v 1.5 channels with the voltage step shown in the inset before and after application of 1 μM PP2, and PP2 plus 1 mM orthovanadate. PP2 gradually increased hK v 1.5 current, and the effect was gradually reversed by orthovanadate. The inhibition of I Kur and hK v 1.5 current at +50 mV are shown in Figure 5D . Human atrial I Kur was increased by PP2 (n = 6, P < 0.05), and the effect was reversed by orthovanadate, while hK v 1.5 current was similarly increased by PP2 (n = 7, P < 0.05) and was reversed by orthovanadate. These results indicate that PP2 slightly, but significantly, increased I Kur /hK v 1.5 current in a PTKdependent manner.
Tyrosine phosphorylation of hK v 1.5 channels
If the suppression of I Kur /hK v 1.5 channels by genistein and AG556 or the increase of I Kur /hK v 1.5 channels by PP2 is mediated by EGFR kinase inhibition or Src family kinases reduction, tyrosine phosphorylation of the channel would be reduced by these PTK inhibitors. The tyrosine phosphorylation of hK v 1.5 protein was therefore determined in HEK 293 cells stably expressing hK v 1.5 channels, but not in human atrial myocytes due to the limited cells isolated from human atrial specimens. Figure 6A displays the tyrosine phosphorylation images of hK v 1.5 channels in the HEK 293 cells treated with 1 mM orthovanadate, 30 μM genistein, genistein plus orthovanadate, 10 μM AG556, AG556 plus orthovanadate, 1 μM PP2 or PP2 plus orthovanadate (30 min). Genistein, AG556 and PP2 significantly decreased the phosphorylation level of hK v 1.5 channel protein, and the reduction in phosphorylation was reversed by pretreatment (30 min) with 1 mM orthovanadate. Orthovanadate itself had no effect on phosphorylation levels of the hK v 1. (E) Percentage values of hKv1.5 current (at +50 mV) in the absence (control) and presence of 30 μM genistein or genistein plus OV (n = 9). *P < 0.05, significantly different from control; #P < 0.05, significantly different from genistein alone, OV alone (n = 5), 10 μM AG556 and AG556 plus 1 mM OV (n = 8). *P < 0.05, significantly different from control; #P < 0.05, significantly different from AG556 alone). 2011a) and hK v 4.3 channels , is saturated under basal physiological conditions. Figure 6B summarises the mean levels of hK v 1.5 tyrosine phosphorylation. Orthovanadate itself had no effect on the saturated tyrosine phosphorylation of hK v 1.5 channels. Genistein (30 μM) decreased the tyrosine phosphorylation of hK v 1.5 channel protein (n = 5, P < 0.05 vs. vehicle control), and the reduction was countered by 1 mM orthovanadate (P < 0.05 vs. genistein alone). AG556 (10 μM) decreased the tyrosine phosphorylation (n = 5, P < 0.05 vs. control) and this effect was reversed by 1 mM orthovanadate (P < 0.05 vs. AG556 alone). PP2 (1 μM) decreased the tyrosine phosphorylation level (n = 5, P < 0.05 vs. control) and the inhibition was reversed by co-application of orthovanadate (P < 0.05 vs. PP2 alone). These results indicate that the inhibition of hK v 1.5 Potential tyrosine phosphorylation sites of hK v 1.5channels
To determine the potential EGFR tyrosine phosphorylation sites of hK v 1.5 channels, we initially generated three mutants (Y155F, Y521F and Y601F) of predicted tyrosine phosphorylation sites and tested the inhibitory response of these mutants to the selective EGFR kinase inhibitor AG556. The wild-type (WT) hK v 1.5 and the mutant currents recorded in HEK 293 cells transiently expressing the corresponding hK v 1.5 channel mutants are displayed in Figure 7A -D in the absence and presence of 10 μM AG556. It appears that current density is greater in WT hK v 1.5 channels than in hK v 1.5 mutants (Table 1 , n = 7-12, P < 0.05). The sensitivity of Y155F, Y521F and Y601F to AG556 was reduced, which suggests that Y155, Y521 and Y601 may be the EGFR kinase phosphorylation sites. However, the triple mutant Y155F-Y521F-Y601F of hK v 1.5 channels still showed a significant inhibitory response to 10 μM AG556, though it was more sensitive to AG556 (P < 0.05 vs. other mutants). This differs from the hK v 10.1 channels, in which triple tyrosine phosphorylation site mutation abolishes the inhibitory response to AG556 . These results suggest that the tyrosine phosphorylation sites of hK v 1.5 channels are not limited to Y155, Y521 and Y601.
Figure 6
Tyrosine phosphorylation levels of hK v 1.5 channels. (A) Images of immunoprecipitation (IP) and western blot (WB) in cells treated with vehicle (control), 1 mM orthovanadate (OV), 30 μM genistein, genistein plus 1 mM OV, 10 μM AG556, AG556 plus 1 mM OV, 1 μM PP2 and PP2 plus OV. (B) Relative phosphorylated hK v 1.5 levels were determined by dividing pTyr-K v 1.5 density by total hK v 1.5 protein density in cells treated with OV, genistein, AG556 or PP2 as described in (A) and then normalizing to vehicle control (n = 5). *P < 0.05, significantly different from vehicle control; #P < 0.05, significantly different from genistein, AG556 or PP2 alone.
Figure 7
Effects of AG556 on mutant hK v 1.5 channels. (A) WT hK v 1.5 current recorded with the voltage protocol as shown in Figure 4A in a representative cell treated with 10 μM AG556; bar graph shows WT hK v 1.5 current densities at +50 mV (n = 12). *P < 0.05, significant effect of AG556). (B) Y155F current recorded in a representative cell treated with 10 μM AG556; bar graph shows Y155F current densities at +50 mV (n = 9). *P < 0.05, significant effect of AG556). (C) Y521F current recorded in a representative cell treated with 10 μM AG556; bar graph shows Y521F current densities at +50 mV (n = 8). *P < 0.05, significant effect of AG556). (D) F601F current recorded in a representative cell treated with 10 μM AG556; bar graph shows Y601F current densities at +50 mV (n = 8). *P < 0.05, significant effect of AG556). (E) Y155F-Y521F-Y601F current recorded in a representative cell treated with 10 μM AG556; bar graph shows the triple mutant current densities at +50 mV (n = 7). *P < 0.05, significant effect of AG556). 
Discussion
It is well known that PTKs not only modulate cell growth and differentiation (Hubbard and Till, 2000) but also regulate ion channels (Davis et al., 2001) . Earlier studies have used the inhibitors of receptor TKs, for example, the isoflavone genistein and the tyrphostin compounds (Levitzki and Mishani, 2006) , or the non-receptor TK (e.g. Src family kinases) inhibitor PP2, and/or a protein tyrosine phosphatase inhibitor (e.g. orthovanadate) in different types of cells and investigated the regulation of a number of ion channels and currents by TKs, including L-type Ca 2+ current (I Ca.L ) in cardiac myocytes (Ogura et al., 1999) , volume-sensitive chloride current (I Cl.vol ) in dog and human atrial cardiac myocytes (Sorota, 1995; Du et al., 2004) , cardiac voltage-gated Na + current (I Na ) (Liu et al., 2007) and several types of K + channels in different types of cells Zhang et al., 2008 Zhang et al., , 2011a Zhang et al., ,b, 2012 Dong et al., 2010; Wu et al., 2012 Wu et al., , 2013 . In the present study, the Src family kinase inhibitor PP2 slightly increased human atrial I Kur and hK v 1.5 current expressed in HEK 293 cells and significantly inhibited tyrosine phosphorylation of hK v 1.5 channels and the effects were countered by the protein tyrosine phosphatase inhibitor orthovanadate, suggesting that endogenous tyrosine phosphorylation of hK v 1.5 channels by Src family kinases would inhibit I Kur /hK v 1.5 current. This notion is supported by the early report of a direct association of Src TK with native hK v 1.5 channels in human myocardium and cloned hK v 1.5 channels. This occurred at a proline-rich motif of the channel and the SH3 domain of Src, and tyrosine phosphorylation of hK v 1.5 channels suppressed the channel current in cells coexpressing v-Src (Holmes et al., 1996) . A recent study found that removing this proline-rich region resulted a mutant hK v 1.5 channel with reduced current and lack of response to v-Src-induced current reduction, which suggests the abnormal atrial repolarization control due to variable Src family TK signalling as a mechanism in familial atrial fibrillation (Yang et al., 2010) . A more recent report demonstrated that activation of the TK JAK3 down-regulated K v 1.5 channels with an effect similar to Src family kinases (Warsi et al., 2015) .
The present study provided new evidence that I Kur /hK v 1.5 current may also be regulated by EGFR kinase. Genistein is a broad-spectrum PTK inhibitor. It strongly inhibits EGFR kinase and also the Src family kinases (Akiyama and Ogawara, 1991) , and is widely utilized for investigating ion channel regulation by PTKs (Ogura et al., 1999; Gao et al., 2004) . The present study showed that genistein did not increase but inhibited I Kur /hK v 1.5 current. PTK-independent suppression by genistein has been previously observed in cardiac I Ks (Washizuka et al., 1998) , I Kr (Missan et al., 2006) , neuronal I Na (Liu et al., 2004) , K ir 2.1 and K ir 2.3 channels (Zhao et al., 2008) and K v 4.3 channels expressed in CHO cells (Kim et al., 2011) . However, PTK-dependent inhibition of human cardiac I Ks and hERG channels and hK ir 2.1, hK ir 2.3 and hK v 4.3 channels by genistein was revealed by the application of the protein tyrosine phosphatase inhibitor orthovanadate and the determination of tyrosine phosphorylation levels of these channel in our earlier reports Dong et al., 2010; Zhang et al., 2011a Zhang et al., ,b, 2012 . In this study, we found that genistein (3-100 μM) inhibited human atrial I Kur in a concentration-dependent manner. The reduction of I Kur /hK v 1.5 current by 30 μM genistein was significantly reversed by orthovanadate. A small fraction of PTKindependent inhibitory action of genistein is also involved in the overall inhibition of I Kur /hK v 1.5 current. This suggests that the effects of 30 μM genistein on I Kur /hK v 1.5 current is mainly due to inhibition of EGFR kinase, which was confirmed with the selective EGFR kinase inhibitor AG556.
AG556 is a highly selective inhibitor of EGFR TK (Levitzki and Mishani, 2006) . Earlier studies demonstrated that AG556 can inhibit EGFR kinase activation and thereby improve rat spinal cord injury (Usul et al., 2004) and cardiac arrhythmias (Feng et al., 2012) induced by ischaemia/reperfusion injury accompanied with EGFR activation. Also, AG556 reversed the EGF-induced enhancement of cardiac I Na (Liu et al., 2007) and K ir 2.3 current (Zhang et al., 2011b) . In the present study, we demonstrated that AG556 inhibited human atrial I Kur in a concentration-dependent manner. The decrease of I Kur /hK v 1.5 current by 10 μM AG556 is mainly due to inhibiting EGFR TK, though a small fraction of PTKindependent effect cannot be excluded. The EGFR TK inhibition is supported by the evidence that the reduced current and tyrosine phosphorylation level by AG556 are reversed by the protein tyrosine phosphatase inhibitor orthovanadate. Tyrosine phosphorylation of hK v 1.5 channels by EGFR kinase activates the channel and may thereby enhance the current. However, orthovanadate did not affect I Kur /hK v 1.5 current or the channel phosphorylation level, which suggests the basal tyrosine phosphorylation of hK v 1.5 channels is saturated, as observed in rat cardiac K v currentS , human cardiac I to , hERG , I Ks (Dong et al., 2010) , K ir 2.1 (Zhang et al., 2011a) and also hEAG1 and hSKCa1 (Wu et al., 2013) .
I Kur is a rapidly activating, delayed rectifier current in response to depolarization, is predominantly present in human atria (Li et al., 1996b) and is responsible for human atrial repolarization (Feng et al., 1997; Wettwer et al., 2004; Li et al., 2008) . Previous studies demonstrate that hK v 1.5 channels can be down-regulated by Src family kinases (Holmes et al., 1996; Yang et al., 2010) . In this study, we showed that in addition to Src family kinase regulation, EGFR TK also regulates I Kur /hK v 1.5 current. EGFR TK and Src kinases regulate I Kur / hK v 1.5 current with opposite actions. Under physiological conditions, control by EGFR kinase is clearly dominant (increasing the current). The basal full-stoichiometric phosphorylation of hK v 1.5 channels with other K + channels (K ir 2.1, K ir 2.3, I Kr , I Ks ) is responsible for maintaining normal human atrial repolarization. So inhibition of EGFR tyrosine phosphorylation of these K + channels by genistein and/or AG556 would decrease the current amplitude and therefore delay human atrial repolarization. On the other hand, under pathophysiological conditions, control by Src kinases may be important. Recent studies have demonstrated that loss-offunction and/or gain-of function mutations of hK v 1.5 channels increase susceptibility to atrial fibrillation (Olson et al., 2006; Christophersen et al., 2013) . Abnormal Src kinase phosphorylation of hK v 1.5 channels is implicated in familial atrial fibrillation (Yang et al., 2010) . In addition, K v 1.5 current plays a role in the maintenance of the cell membrane potential in a wide variety of cells/tissues, such as pancreatic beta cells (MacDonald and Wheeler, 2003) , brain tissue (Tipparaju et al., 2012) , macrophages (Vicente et al., 2006) and skeletal muscle (Kang et al., 2009) , as well as smooth muscles in vessels (Overturf et al., 1994) and airways (Adda et al., 1996) . Therefore, tyrosine phosphorylation of hK v 1.5 channels could also be important in maintaining normal cellular function of these types of cells. Moreover, K v 1.5 channels are also expressed in several tumour cells and participate in the modulation of cell adhesion, proliferation and apoptosis (Bonnet et al., 2007; Ousingsawat et al., 2007; Arvind et al., 2012) . Thus, K v 1.5 channels has been considered to be a potential target to regulate tumour growth (Felipe et al., 2012) . Inhibition of K v 1.5 channel activity via EGFR inhibitors is a possible pathway for the clinical treatment of cancers (Tan et al., 2015) .
A major limitation of this study was that we did not identify all of the tyrosine phosphorylation sites involved in the EGFR kinase phosphorylation of hK v 1.5 channels. The mutants Y155F, Y521F and Y601F showed a reduced response to AG556 inhibition. However, the triple mutant Y155F-Y521F-Y601F did not completely eliminate the inhibitory response to 10 μM AG556 (À29.4%). The small fraction (8.5%) of PTK-independent inhibition of hK v 1.5 channels by 10 μM AG556 cannot account for the significant inhibition of the triple mutant, which suggests that in addition to Y155, Y521 and Y601, other tyrosine sites may also be involved in EGFR kinase phosphorylation.
The tyrosine phosphorylation of hK v 1.5 channels by EGFR TKs is clearly not simple as EGFR kinase phosphorylation of cardiac K ir 2.1, K ir 2.3 and SKCa1, in which only one tyrosine site is involved in EGFR kinase phosphorylation (Zhang et al., 2011a,b; Wu et al., 2013) . A similar phenomenon was also observed in cardiac I Ks in which several tyrosine sites are involved in EGFR kinase phosphorylation of KCNQ1 (Missan et al., 2009) . Another limitation was that we were unable to obtain data on the changes in tyrosine phosphorylation in mutant hK v 1.5 channels because our very low transfection rate (typically <10%) precluded biochemical analysis by immunoprecipitation and Western blotting. Although mass spectrometry can be used to accurately determine the specific levels of protein phosphorylation in tiny amounts of sample (Mann et al., 2002) , we were not able to employ such approaches in the present study. The levels of tyrosine phosphorylation associated with the data reported in this paper remain to be determined.
Collectively, the present study provides the first indication that PTKs show dual regulating effects on I Kur /hK v 1.5 current. Src family kinases decrease but EGFR kinase increases the activity of I Kur /hK v 1.5 channels. This information is important not only for understanding cardiac electrophysiological regulation by PTKs but also for interpreting the therapeutic potential of PTK inhibitors in humans, especially EGFR inhibitors.
